Hims & Hers Health shares moved notably higher in morning trading, rising 6.5% to $34.05 as momentum from a fresh Barclays analyst upgrade continued to influence the market.
Barclays analyst Glen Santangelo lifted his price target on the stock to $39 from $29 and kept an Overweight rating. In his note, Santangelo pointed to what he described as a "clear inflection" in the companys GLP-1 weight-loss business following Hims & Hers partnership with Novo Nordisk that was announced in March. Supporting data cited by the analyst included a 35% year-over-year rise in website traffic in May and a 21% increase in monthly active app users over the same period.
Beyond the Barclays call, market participants are eyeing an upcoming FDA Pharmacy Compounding Advisory Committee meeting on July 23-24. The panel will consider whether seven peptides should be added to the 503A bulk substances list. Analysts referenced in market commentary view a favorable committee outcome as a potential new growth channel for Hims & Hers outside of its existing GLP-1 compounding operations. Some projections noted by market observers suggest that if Hims & Hers were to secure even a modest portion of the combined peptide market, it could translate into meaningful long-term revenue growth for the company.
Corporate developments have also contributed to the constructive tone. Hims & Hers recently appointed Dr. Anant Vinjamoori as Chief Medical Officer, a move seen by investors as bolstering the companys clinical credentials. The company also completed its acquisition of Eucalyptus, a transaction that extends Hims & Hers commercial footprint across the U.S., the U.K., Australia, Canada, and several other international markets.
The broader trading environment provided additional support for higher-risk growth names during the session. The S&P 500 advanced roughly 0.8% while the Nasdaq climbed about 1.2%. Market participants noted that the Federal Reserve held interest rates steady in its first policy decision under new Chair Kevin Warsh, an outcome that eased some near-term monetary policy uncertainty and appeared to encourage risk appetite among investors in healthcare and technology sectors.
Taken together, the Barclays upgrade and its cited engagement data - combined with the potential FDA peptide catalyst and a benign macro backdrop - pushed Hims & Hers above its recent trading range. At the time of reporting, the stock was trading comfortably above its opening price of $32.60 and had reached a session high of $34.59. Despite the intraday strength, the share price remains well below its 52-week high of $70.43, leaving market participants to watch whether the companys expected second-half growth materializes in line with Barclays view.
Summary
Hims & Hers rose after a Barclays price-target increase and sustained investor focus on an FDA advisory committee vote that could broaden compounding opportunities. Company hires and its acquisition of Eucalyptus further supported the stock.
Key points
- Barclays raised its price target to $39 from $29 and maintained an Overweight rating, citing an inflection in GLP-1 engagement.
- An FDA advisory committee meeting on July 23-24 could add seven peptides to the 503A list, a potential new growth avenue for Hims & Hers beyond GLP-1 compounding.
- Corporate moves, including the appointment of Dr. Anant Vinjamoori as Chief Medical Officer and the completion of the Eucalyptus acquisition, have contributed to improved investor sentiment.
Risks and uncertainties
- The FDA advisory committee could reach a decision that does not add the seven peptides to the 503A bulk substances list, which would limit the potential new market opportunity referenced by analysts.
- Execution risk remains if the companys anticipated second-half growth does not materialize as Barclays expects, leaving the stock vulnerable given its distance from the 52-week high.